David Dean Halbert is a prominent American entrepreneur and the founder of Caris Life Sciences. Born in 1956, Halbert grew up with a strong interest in business and technology, eventually earning a Bachelor of Business Administration from Abilene Christian University.

His early career was marked by a fundamental belief that advanced molecular technology could revolutionize the way human diseases are diagnosed and treated—a vision that became the cornerstone of his multi-billion dollar ventures.

• Core Company: Caris Life Sciences.
• Education: BBA from Abilene Christian University.
• Honors: Recipient of a Doctorate of Science (h.c.) for his contributions to life sciences.

David Dean Halbert’s career transition from pharmacy services to high-tech diagnostics is a masterclass in business scaling. In 1987, he founded AdvancePCS, which grew into a leading pharmacy benefits management company. He took the firm public and later sold it to Caremark for $7.5 billion in 2004.

Following this massive exit, Halbert acquired the Molecular Profiling Institute in 2008, which he renamed Caris Life Sciences. Under his leadership as Chairman and CEO, Caris became a leader in precision medicine, utilizing AI and machine learning for early disease detection. By 2024, the company’s annual revenue grew to $412 million.

• Role: Founder, Chairman, and CEO of Caris Life Sciences.
• Major Achievement: Architect of a $7.5 billion sale of AdvancePCS.